These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 2510972)

  • 1. Conjugate vaccines against Pseudomonas aeruginosa and malaria.
    Cryz SJ; Sadoff JC; Que JU
    Contrib Microbiol Immunol; 1989; 10():166-89. PubMed ID: 2510972
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunologic considerations for the development of conjugate vaccines.
    Garner CV; Pier GB
    Contrib Microbiol Immunol; 1989; 10():11-7. PubMed ID: 2510971
    [No Abstract]   [Full Text] [Related]  

  • 3. Contemporary trends in conjugate vaccine development.
    Cruse JM; Lewis RE
    Contrib Microbiol Immunol; 1989; 10():1-10. PubMed ID: 2510970
    [No Abstract]   [Full Text] [Related]  

  • 4. Mouse-protection experience with monovalent Pseudomonas aeruginosa vaccine.
    Sourek J; Výmola F; Zelenková L
    Zentralbl Bakteriol A; 1980 Mar; 246(3):353-62. PubMed ID: 6775443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudomonas aeruginosa. II. Experimental acellular vaccine of an endotoxin and anatoxin type.
    Bĕlohlávek S; Pavlík V; Rencová J; Stránský V; Nováková L; Sourek J; Výmola F
    J Hyg Epidemiol Microbiol Immunol; 1987; 31(3):343-52. PubMed ID: 3119704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines against Pseudomonas aeruginosa results and perspectives of investigations (survey).
    Joó I; Stanislavskii ES
    J Hyg Epidemiol Microbiol Immunol; 1982; 26(4):417-27. PubMed ID: 6819316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cellular basis of the immune response to conjugate vaccines.
    Bixler GS; Pillai S
    Contrib Microbiol Immunol; 1989; 10():18-47. PubMed ID: 2684506
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
    Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT
    Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pseudomonas aeruginosa preparations for active immunization].
    Nazarchuk LV
    Vrach Delo; 1991 Jul; (7):22-7. PubMed ID: 1771827
    [No Abstract]   [Full Text] [Related]  

  • 10. Background and indications for Haemophilus influenzae type b vaccines consisting of capsular antigen coupled to protein carriers.
    Anderson PW; Stein EC; Insel RA
    Contrib Microbiol Immunol; 1989; 10():115-24. PubMed ID: 2684504
    [No Abstract]   [Full Text] [Related]  

  • 11. Recent trends in the developments of bacterial vaccines.
    Lindberg AA; Pillai S
    Dev Biol Stand; 1996; 87():59-71. PubMed ID: 8854003
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness of immunization with single and multi-component vaccines prepared from a common antigen (OEP), protease and elastase toxoids of Pseudomonas aeruginosa on protection against hemorrhagic pneumonia in mink due to P. aeruginosa.
    Homma JY; Abe C; Tanamoto K; Hirao Y; Morihara K; Tsuzuki H; Yanagawa R; Honda E; Aoi Y; Fujimoto Y; Goryo M; Imazeki N; Noda H; Goda A; Takeuchi S; Ishihara T
    Jpn J Exp Med; 1978 Apr; 48(2):111-33. PubMed ID: 101698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active and passive mouse-protecting capacity of Pseudomonas aeruginosa protein vaccines.
    Joó I; Stanislavsky ES; Zhvanetskaya MI; Mashilova GM; Gladus MA
    Acta Microbiol Acad Sci Hung; 1982; 29(4):267-75. PubMed ID: 6821018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new polyvalent pseudomonas vaccine.
    Merle P; Robbel L; Hungerer KD
    Behring Inst Mitt; 1984 Nov; (76):113-20. PubMed ID: 6441560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. O-polysaccharide-protein conjugates induce high levels of specific antibodies to Pseudomonas aeruginosa immunotype 3 lipopolysaccharide.
    van de Wiel PA; Witvliet MH; Evenberg D; Derks HJ; Beuvery EC
    Vaccine; 1987 Mar; 5(1):33-8. PubMed ID: 2437718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective characteristics of the antigen common to Pseudomonas and Vibrio and significance of bacterial endotoxins in protection against selected bacterial infections.
    Sourek J
    Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Jul; 259(4):538-47. PubMed ID: 2413656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunogenic properties and specificity of pseudomonas aeruginosa polyvalent vaccine].
    Schiller B; Lysakowska E; Owczarska K
    Med Dosw Mikrobiol; 1981; 33(2):91-6. PubMed ID: 6170849
    [No Abstract]   [Full Text] [Related]  

  • 18. Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans.
    Cryz SJ; Sadoff JC; Fürer E; Germanier R
    J Infect Dis; 1986 Oct; 154(4):682-8. PubMed ID: 3091708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunogenic properties of a polyvalent vaccine against Pseudomonas aeruginosa].
    Serafińska D; Bukowska D; Sokołowska K; Nasiłowski W
    Pol Tyg Lek; 1980 Jul; 35(27):1013-5. PubMed ID: 6775310
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunogenicity of tetanus toxoid conjugates of anti-idiotypes that mimic Pseudomonas aeruginosa surface polysaccharides.
    Schreiber JR; Dahlhauser P
    Infect Immun; 1994 Jan; 62(1):308-12. PubMed ID: 8262644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.